Science Explorer Back to mapMap
Discussion
Topic · Rheumatology

Soft tissue tumor case studies

Soft tissue tumor case studies is a research topic within Rheumatology. Science Explorer counts 22k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the clinicopathologic characteristics, genetic mutations, and treatment strategies for fibrous tumors such as Solitary Fibrous Tumors and Desmoid Tumors. It discusses the identification of recurrent gene fusions, the distinction from histologic mimics, risk assessment models, and the efficacy of various treatments including surgery, radiation therapy, and targeted therapies.

  • Solitary Fibrous Tumor
  • Desmoid Tumor
  • NAB2-STAT6 gene fusions
  • Surgery
  • Radiation Therapy
  • CTNNB1 mutations
  • Aggressive Fibromatosis
  • Imatinib treatment
  • PDGFRB mutations
  • Prognostic Factors
Research works
22k
fractional, since 1950
In the world top 10%
2.2k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-1%
the tick is no change
Largest producer
United States
29% of the 10 largest, 2022-now
Soft tissue tumor case studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Soft tissue tumor case studies research?

By volume, the United States and India publish the most (665 and 430 works in 2022-now).

By volume, 2022-now

  1. 1 United States 665 works
  2. 2 India 430 works
  3. 3 China 383 works
  4. 4 Japan 237 works
  5. 5 Spain 105 works
  6. 6 Brazil 104 works
  7. 7 Germany 100 works
  8. 8 Italy 99 works
  9. 9 Türkiye 91 works
  10. 10 United Kingdom 86 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 28.9%India: 18.7%China: 16.7%Japan: 10.3%6 others listed: 25.4%29%largest
United States665 · 28.9%India430 · 18.7%China383 · 16.7%Japan237 · 10.3%6 others listed585 · 25.4%

Shares of the rows listed above, not of the whole node.

Which institutions lead Soft tissue tumor case studies research?

By volume in 2022-now, All India Institute of Medical Sciences publishes the most Soft tissue tumor case studies research, followed by Harvard University and Mayo Clinic.

By volume, 2022-now

  1. 1 All India Institute of Medical SciencesIndia 52 works
  2. 2 Harvard UniversityUnited States 29 works
  3. 3 Mayo ClinicUnited States 21 works
  4. 4 Sichuan UniversityChina 17 works
  5. 5 Mohammed V UniversityMorocco 16 works
  6. 6 Stanford UniversityUnited States 12 works
  7. 7 University of DelhiIndia 12 works
  8. 8 Mount Sinai Health SystemUnited States 12 works
  9. 9 Zhejiang UniversityChina 11 works
  10. 10 University of MiamiUnited States 11 works

Who are the leading researchers in Soft tissue tumor case studies?

The most-cited researchers publishing on Soft tissue tumor case studies include Elaine R. Mardis, Matthew M. Meyerson and Patrick M. Bossuyt.

  1. 1 Elaine R. Mardis United States 346k citations
  2. 2 Matthew M. Meyerson United States 280k citations
  3. 3 Patrick M. Bossuyt Netherlands 270k citations
  4. 4 Jean‐Louis Vincent Belgium 262k citations
  5. 5 Kai You Wang China 224k citations
  6. 6 Dirk Schadendorf Germany 222k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Soft tissue tumor case studies?

The most cited paper in Soft tissue tumor case studies is "Case report 3" (Murray K. Dalinka, R. E. Brennan, Arthur S. Patchefsky, 1976), with 4,090 citations. Next come "A System for the Surgical Staging of Musculoskeletal Sarcoma" (2,513) and "Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor" (2,319).

Most cited papers
#PaperReleasedCitations
1 Case report 3 Murray K. Dalinka, R. E. Brennan, Arthur S. Patchefsky · Skeletal Radiology 1976 4,090
2 A System for the Surgical Staging of Musculoskeletal Sarcoma William F. Enneking, Suzanne S. Spanier, MARK A. GOODMAN · Clinical Orthopaedics and Related Research Nov 1980 2,513
3 Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Michael Charles Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology 25 Nov 2003 2,319
4 Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis Markku Miettinen, Jerzy P. Lasota · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin Open access 15 Jan 2001 1,872
5 Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients Margaret R. Wallace, Douglas A. Marchuk, Lone B. Andersen et al. · Science 13 Jul 1990 1,488
All 100 most cited papers, with filters and sorting

Where is Soft tissue tumor case studies research done?

The largest centres of Soft tissue tumor case studies research in 2022-now are New Delhi (India), Tokyo (Japan), Beijing (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Rabat.

Largest cities, 2022-now

  1. 1 New DelhiIndia 56 works
  2. 2 TokyoJapan 43 works
  3. 3 BeijingChina 41 works
  4. 4 New YorkUnited States 41 works
  5. 5 IstanbulTürkiye 31 works
  6. 6 LondonUnited Kingdom 30 works
  7. 7 ShanghaiChina 28 works
  8. 8 MumbaiIndia 27 works
  9. 9 SeoulSouth Korea 27 works
  10. 10 São PauloBrazil 25 works

Where it is the local speciality

  1. RabatMA · 24.7 works12×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Soft tissue tumor case studies than the world average.

See Soft tissue tumor case studies on the map

Where is the best place to study Soft tissue tumor case studies?

Among universities, judged by research, Harvard University, University of Toronto and All India Institute of Medical Sciences score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%60%mean 22.69%fractional works in this field (log) →share of work in the world top 10% →University of TorontoHarvard UniversityStanford UniversityAll India Institute …
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 67.233.8%3.1×29 -20.9%
2University of TorontoCanada 54.449.0%1.7×10 -18.5%
3All India Institute of Medical SciencesIndia 53.84.8%16.4×52 +52.0%
4Stanford UniversityUnited States 52.528.5%2.9×12 +32.7%
5Heidelberg UniversityGermany 50.722.3%4.7×10 +24.1%
6University of MiamiUnited States 45.922.3%6.2×11 +41.4%
7The Ohio State UniversityUnited States 41.821.8%2.9×10 +30.4%
8Sichuan UniversityChina 41.317.8%2.6×17 +36.1%
9University of California, Los AngelesUnited States 37.414.2%3.0×10 +77.7%
10University of MichiganUnited States 36.512.4%1.9×8 +56.6%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Soft tissue tumor case studies, country by country

Is Soft tissue tumor case studies research growing?

Output in 2022-2025 was 1% lower than in 2018-2021, peaking in 2020.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Soft tissue tumor case studies as a percentage of every work published that year, 0.015% in 2024.

still counting0.020%0.040%Soft tissue tumor case studies0.013% in 202519801990200020102020

Fractional works of Soft tissue tumor case studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Soft tissue tumor case studies10.4% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Soft tissue tumor case studies. Posts are plain text and can be reported.